ASCO® 2023 Summary: "Latest in PARPi in Prostate Cancer - PROpel, TA…

ecancer

R. McKay, F. Schlürmann, G. von Amsberg

ASCO® 2023 Insights: "Prognostic Impact of PSA Nadir (n)≥0.1ng/mL Wi…

Dana-Farber Cancer Institute

P. Ravi

ASCO® 2023 Poster Sessions From Dr. Andrew Armstrong in Prostate Can…

Insights from 2023 ASCO® Annual Meeting

A. Armstrong

ASCO® 2023 Insights: "PSMAddition - A Phase 3 Trial to Compare Treat…

Insights from 2023 ASCO® Annual Meeting

S. Tagawa

Dana-Farber Cancer Institute Prostate Cancer Updates From ASCO GU 20…

Dana-Farber Cancer Institute

J. Berchuck, A. Choudhury

A Multidisciplinary Team Approach to Prostate Cancer

Judd Moul

ASCO GU 2023 DEAR Study: Real-World Use of Darolutamide, Enzalutamid…

ASCO GU 2023 Conference Coverage

D. George

2023 West Oncology Conference: Latest Updates in Advanced Prostate C…

2023 West Oncology Conference

B. Somer

ASCO GU 2023 Latest in HSPC

ecancer

E. Efstathiou, B. Hadaschik, G. Attard, H. Payne

Efficacy and Safety of Darolutamide in Combination With ADT and Doce…

ASCO GU 2023 Conference Coverage

C. Sternberg

Advances in the Treatment Landscape of Metastatic Prostate Cancer

OncoAlert

N. Agarwal

ASCO GU 2023 Active Surveillance for Favorable Intermediate-Risk Pro…

ASCO GU 2023 Conference Coverage

A. D'Amico

ARASENS Trial Updates: OS With Darolutamide vs. Placebo in Combinati…

Fred Saad

Phase 3 ARASENS Trial: Overall Safety & Incidences of Adverse Events…

E. David Crawford

In Pursuit of Precision Medicine for Prostate Cancer Patients: Recen…

Houston Methodist

E. Efstathiou

AR Antagonists for Prostate Cancer: Are They All Equal?

PROSCA & BLADDR 2022

B. Tombal

Treatment Approach for Patients With mCSPC

PrecisCa

M. Rettig

When to Use Genomic Testing for Prostate Cancer

PrecisCa

P. Patel